Scientists hunt for new eye disease marker in fluid samples
NCT ID NCT03680794
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study measures levels of a protein called sCD160 in eye fluid and blood samples from 120 adults with diabetic retinopathy or retinal vein occlusion. Researchers want to see if sCD160 levels are linked to the severity of these eye conditions. Participants provide samples during routine eye surgery and undergo imaging tests. No treatment is given.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify sCD160 as a marker for eye disease severity, potentially guiding future treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures protein levels and does not test any therapy, so direct patient benefit is unlikely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu Reims
RECRUITINGReims, 51092, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI eye doctor: could software catch diabetic blindness sooner?
- Can eye scans reveal hidden clues about diabetes damage?
- Herbal formula plus eye injections: a new hope for blocked retinal veins?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug aims to restore vision in Diabetes-Related swelling
- New eye drug aims to restore vision in Diabetes-Related swelling